Kornimate/medical-research-clean huggingface dataset:
evaluation of the patient experience with a surgically-assisted acceleration method of orthodontic treatment

Conditions: Crowding, Tooth

Summary: the duration of orthodontic treatment is one of the exacerbation causes of orthodontic pain. several methods have been suggested to reduce the duration of orthodontic treatment classified to surgical and non-surgical methods. researches used minimally invasive surgical methods like corticision, piezocesion, disicion, micro-osteoperforation, and piezopuncture indicated that most of these methods can accelerate dental movement by 20 - 40% without causing additional pain as a result of using those methods. applying corticision on the lower anterior teeth using a surgical blade and a hammer may accelerate tooth alignment during orthodontic treatment. this study consists of two groups, patients will be randomly assigned to one of these two groups.

pain is defined as an unpleasant emotional sensory experience associated with actual or potential harm. it was mentioned as one of the most common complaints related to orthodontic treatment, and around 65-95% of patients undergoing orthodontic treatment suffer from various degrees of pain. corticision is one of the minimally invasive surgical procedures that is not associated with flap lifting. it was used to accelerate tooth movement in animals and case report studies. its application on humans may aggravate their fear and anxiety towards the pain that may accompany this technique. no study in the literature has been searched in patient perception of pain, discomfort, levels of acceptance and satisfaction accompanied corticision application application, but in this study, these previous variables accompanied corticision technique have been studied on crowded lower anterior teeth cases which are one of the most common types of malocclusions.

Eligibility criteria:
inclusion criteria: 1. age range between 18 and 24 years 2. completion of permanent dentition (except third molars) 3. mild to moderate crowding (2-6 mm according to little's index) 4. absence of medications intake that interferes with pain perception for at least one week before the beginning of the treatment exclusion criteria: 1. systematic diseases that could affect bone and tooth movement and no contraindication avoid oral surgery 2. medical conditions that affect tooth movement (corticosteroid, nsaids) 3. patients had previous orthodontic treatments 4. poor oral hygiene or concurrent periodontal disease

Keywords: corticision visual analog scale mild and moderate crowding surgical blade pain discomfort
conventional double-lumen tube vs vivasight dl

Conditions: Endotracheal Intubation

Summary: the investigators sought to compare the time to intubation and success rate of the endotracheal intubation using standard double-lumen tube and video tube etview dl in an adult cadaver model in normal and difficult airway conditions.


Eligibility criteria:
inclusion criteria: * fresh adult cadavers exclusion criteria: * cadavers with face injures
acute defibrillation study

Conditions: Ventricular Arrhythmias

Summary: the proposed study is designed to characterize defibrillation efficacy in humans for the potential development of a new extravascular implantable cardioverter defibrillator (icd) system.

the study recruited male and female subjects that met all of the inclusion criteria and none of the exclusion criteria. all subjects were scheduled to undergo surgical procedures outlined in the inclusion criteria. these surgical procedures were chosen as the patient population for this study because these procedures require similar personnel and may require access to similar or the same spaces as the asd procedure. the entire asd study research system was removed prior to proceeding with the subject's planned surgery per standard medical practice, which then proceeded according to the standard of care. subjects were followed through their routine post-surgery follow-up visit. at the time of completing the follow-up visit, the subjects' participation was complete and the subjects exited the study.

Eligibility criteria:
inclusion criteria: * subject must be undergoing surgical procedure for approved indications for * cardiothoracic surgery where a midline sternotomy is planned, or * implant of a transvenous (tv) icd or subcutaneous icd (s-icd®), or * vt ablation procedure, or * vt inducibility testing during electrophysiology (ep) study * subject must be willing to provide informed consent * subject must be ≥ 18 years old exclusion criteria: * subject is considered to be at high risk for infection * subject has left ventricular ejection fraction (lvef) ≤ 20% * subject at high risk of stroke * subject with an implanted active cardiac or non-cardiac device during study procedure (e.g., icd, s-icd®, pacemaker, neuro stimulator) * subject is pacemaker dependent * subject had previous pericarditis or prior sternotomy * subject has hiatus hernia or moderate or worse pectus excavatum * subject has hypertrophic cardiomyopathy * subject has severe aortic stenosis * subject has severe proximal three vessel coronary disease (over 70% in each vessel) * subject has \>50% left main stem (lms) disease * subject has known skin irritations to the physio control fast patch ecg electrode * subject is enrolled in a concurrent study that may confound the results of this study, without documented pre-approval from a medtronic study manager * subject has medical conditions that would limit study participation * subject is pregnant * subject meets exclusion criteria required by local law (e.g. age, breast feeding, etc.)
evaluation of mmr status and pd-l1 expression using specimens obtained by eus-fnb in patients with pancreatic cancer

Conditions: Pancreatic Cancer

Summary: pancreatic ductal adenocarcinoma (pdac) has a suboptimal response to standard therapies that modestly impact survival due to its ability to evade host immune surveillance. emerging evidence has shown that the co-inhibitory receptors, such as programmed death 1 (pd-1), play a critical role in cancer immune-editing. programmed death-ligand 1 (pd-l1) is an immune checkpoint that is often activated in cancer and plays a pivotal role in the initiation and progression of cancer. the advent of immunotherapy, with checkpoint inhibitors, which block pd-l1 interaction between tumor cells and activated t cells, has significantly altered the treatment algorithm for several solid tumors. however, the clinicopathologic significance and prognostic value of pd-l1 in pdac remains controversial. the main technical ground may be that pdac pd-l1 expression quantification is limited to surgical resection specimens and dependent on specific immunohistochemistry (ihc) tests. in addition, pd-l1 expression has not been extensively assessed before surgery in treatment-naive pdac patients, due to the current ihc test requirement for a histologic rather than a cytologic evaluation. however, a recent study showed that eus-fine needle biopsy (fnb) can successfully determine primary pancreas malignancy pd-l1 status. one recently identified subtype within the genomic landscape of pdac is the mismatch repair-deficient (dmmr) tumor. evaluation of dmmr status is particularly important following the fda approval of the pd-1 inhibitor, pembrolizumab, for the treatment of unresectable or metastatic, microsatellite instability-high (msi-h) or dmmr pdac that have progressed following prior treatment, and have no satisfactory alternative treatment options. the objectives of the project will include the assessment of tumor pd-l1/dmmr expression in patients with pdac using eus-fnb samples and the prospective correlation of mmr status and pd-l1 expression with overall survival and progression-free survival of pdac patients.


Eligibility criteria:
inclusion criteria * age 18 to 90 years old * men or women * signed informed consent for eus and eus -fnb * the diagnosis of adenocarcinoma histologically confirmed by fnb * resectable, unresectable, locally advanced and/or metastatic disease exclusion criteria: -previous chemotherapy or radiotherapy

Keywords: eus-fnb, pdl1, mmr
a pilot study to evaluate educational programs to improve fecal incontinence care in nursing homes

Conditions: Fecal Incontinence; Staffs' Attitudes

Summary: the investigators are planning to do a cluster randomized trial to test the effect of different educational programs for staff according to nursing home patients fi (fecal incontinence). since there are very few published trials of treatment of fi in older people, and no rigorously evaluated studies on interventions for fi in nursing homes, or rigorously evaluated continence education program for staff concerning continence care, a pilot study is necessary. the aim for the pilot study is to evaluate feasibility, acceptability and adherence according to the educational intervention, methods used and outcome measures. this is designed to be an external pilot study. external pilot studies are small scale versions of the main study which are not intended to be part of the main study. the pilot intervention period is 3 month.


Eligibility criteria:
inclusion criteria: * nursing homes wards with 24 hour long term care residency, similar nurse/patient ratio and general practitioner consultancy, comparable patient groups according to frailty, comparable ward size according to number of patients and staff. * patients all patients on long term residency (1 month or more) are eligible for measurements. * registered nurses (rn) and authorized social educators (ase) rn's and ase's with position above 50% are eligible according to participation in the educational meeting and to be recruited as a local opinion leader in intervention 2. all staff is invited to the educational outreach meetings throughout the intervention period. exclusion criteria: * nursing homes with diverse staff and patient composition * patients on short term residency * registered nurses (rn) and authorized social educators (ase) rn's and ase's with position less than 50%

Keywords: fecal incontinence attitudes knowledge quality of care
awareness of patients having diabetes mellitus about oral health

Conditions: Awareness

Summary: diabetic patients will be asked to answer a group of questions about the predictors (age, type of diabetes, level of education) and about the outcomes \[knowledge and awareness of the link between diabetes and oral health, and attitude towards maintaining their oral health as diabetics.

the study will recruit patients having diabetes mellitus; where they will be asked to answer a questionnaire after obtaining an informed consent. diabetic patients will be asked to answer a group of questions about the predictors (age, type of diabetes, level of education) and about the outcomes knowledge and awareness of the link between diabetes and oral health, and attitude towards maintaining their oral health as diabetics.

Eligibility criteria:
inclusion criteria: * aged at least 18 years and being diagnosed with diabetes mellitus exclusion criteria: * individuals who refuse to participate in the study
computerized decision support tool for pain management in primary care

Conditions: Chronic Pain

Summary: chronic pain is highly prevalent, compromises quality of life, and increases care utilization. primary care providers are challenged to provide effective treatments, use opioid therapy appropriately, and address the adverse consequences of pain. technology-enabled decision support tools may provide a means to improve pain management in primary care. the objective of this study was to evaluate a novel electronic health record (ehr)-based decision support tool-plus-education intervention for pain management in primary care.

this randomized, wait-list controlled trial evaluated a novel ehr-based system for pain management among patients with chronic pain in six practices of a federally qualified health center network in new york.

Eligibility criteria:
inclusion criteria: 1. treated at the institute for family health 2. spoke english or spanish 3. received one or more prescriptions for an opioid or nonopioid analgesic during the past three months 4. pain screening at the prior three office visits documented scores \>3 on the 0-6 scale (faces, hicks et al., 2001). 5. willingness to complete questionnaires three times 6. a commitment to return to the practice 7. reachable by phone 8. no evidence of psychopathology or cognitive impairment severe enough to prevent informed consent or completing the survey instruments exclusion criteria: -
understanding the role of autoimmune disorders on the initial presentation of cardiovascular disease

Conditions: Myocardial Infarction; Ischemic Stroke; Stroke; Subarachnoid Haemorrhage; Venous Thrombosis; Transient Ischemic Attack; Stable Angina Pectoris; Unstable Angina; Heart Failure; Peripheral Arterial Disease; Abdominal Aortic Aneurysm

Summary: autoimmune diseases are diseases in which inappropriate immune responses that have the capability of harming host cells play an important role. evidence suggests that the presence of certain autoimmune diseases such as rheumatoid arthritis or systematic lupus erythematosus increase the risk of cardiovascular disease (cvd). however, this evidence is inconsistent for autoimmune disorders and no systematic approach has been previously used to study the relationship between a range of common autoimmune disorders and specific forms of cardiovascular diseases such as myocardial infarction, intracerebral and subarachnoid haemorrhage, or venous thrombosis. the investigators will use linked electronic health records to investigate whether commonly diagnosed autoimmune disorders are associated with increased risk of cvd development and whether effects differ in men and women and change with age.

the linkage of clinical practice research datalink (cprd) to the national registry of acute coronary syndromes (the myocardial ischaemia national audit project, minap), hospital episode statistics (hes) and office for national statistics (ons) available through caliber (cardiovascular disease research using linked bespoke studies and electronic records), offers an opportunity to investigate the association between autoimmune disorders and the initial presentation of non-fatal and fatal specific cardiovascular phenotypes. the use of a systematic approach to investigate whether a range of commonly diagnosed autoimmune disorders are independent risk factors for several specific and well defined arterial and venous diseases will help to improve the investigators understanding of the role of autoimmune disorders in development of specific types of cvd in both men and women and in different age groups. it will also provide useful information to improve existing cardiovascular risk prediction methods that are used in clinical practice for patient management.

Eligibility criteria:
inclusion criteria: * one year prior to study entry * 18 years or older * recorded sex * free of symptomatic cardiovascular disease at entry exclusion criteria: * prior cardiovascular disease
uti prophylaxis using bacterial interference following sci

Conditions: Urinary Tract Infections

Summary: urinary tract infection (uti) is the most common infection in patients with sci and is a major cause of morbidity and mortality in this population. the bladder of patients with sci, especially those who have indwelling catheters, is often colonized by bacteria that may or may not cause symptoms of uti. bacteria that do not cause symptoms are usually considered benign colonizers and are often left untreated because they may afford some protection against symptomatic infection with more harmful bacteria. we applied the concept of using benign bacteria to prevent symptomatic infection, so-called bacterial interference, by deliberately colonizing the bladder of patients with sci with a non-pathogenic prototype of escherichia coli (strain 83972). the preliminary results of our va-funded study that compared the rates of symptomatic uti in patients with sci while colonized with e. coli 83972 vs. historical rates of symptomatic uti prior to study enrollment indicated that deliberate colonization of the bladder of patients with sci with e. coli 83972 is safe and very promising as to its ability to prevent symptomatic uti. however, before this innovative approach of bacterial interference can be successfully applied in the population of patients with sci, it is essential to: (a) confirm the ultimate efficacy of bacterial interference by conducting a prospective, randomized, placebo-controlled clinical trial (objective #1); and (b) enhance the practicality of applying this innovative approach in sci patients by delineating the bacterial and host factors that can promote successful colonization with e. coli 83972 (objectives #2-3).

a prospective, randomized, placebo-controlled clinical trial will be conducted. patients who had sustained sci \>18 months earlier, suffer from neurogenic bladder (require intermittent bladder catheterization, an indwelling suprapubic catheter, or an external collection device), and have a history of frequent symptomatic uti (\> 2 episodes during the preceding year) will be eligible for enrollment. exclusion criteria will include urolithiasis, indwelling nephrostomy catheter, indwelling transurethral foley catheter, supravesical urinary diversion, vesicoureteral reflux, conditions anticipated to require antibiotic therapy for chronic recurrent extraurogenital infections (e.g. infected decubitus ulcers), uncontrolled diabetes mellitus and immunosuppression. patients considered unreliable to pursue adequate follow-up and those incapable of giving informed consent will also be excluded. subjects will discontinue all measures to suppress uti for at least two weeks prior to entry into the study. all patients will have a complete history and physical examination, serum creatinine, plain x-ray of the abdomen (kub), and urine culture immediately prior to entry into the study. renal ultrasound and urodynamic evaluation of the urinary tract will also be obtained upon study entry unless they have been performed during the preceding year.

Eligibility criteria:
inclusion criteria: sci uti exclusion criteria:

Keywords: sci uti
comparison of two therapeutic strategies of dermoval in treatment of bullous pemphigus

Conditions: Bullous Pemphigoid

Summary: to compare efficacity and tolerance of two stratégies of dermoval application in treatment of bullous pemphigus.


Eligibility criteria:
inclusion criteria: * age \> 18 * immunoflurescence, histological exam, predictive value according to bullous pemphigus diagnostic * consentment patient exclusion criteria: * age \< 18 * no consentment * localized bullous pemphigus (\<400cm2) * linear iga pemphigus * corticothérapy, immunotherapy * pregnant woman pemphigus
elearning for suicide prevention

Conditions: Suicide

Summary: project wise (workplace integrated support \& education) includes developmental and pilot research to create an e-learning training in suicide safety planning enhanced with novel skill-building technologies that can be integrated into the routine workflow of nurses serving patients hospitalized for medical, surgical, or traumatic injury reasons. this study pilots an initial version of this elearning training and collects data on the acceptability of the training and its components as well as engagement of nurses in the training. the evaluation will inform iterations of the training.


Eligibility criteria:
inclusion criteria: * nurses working in acute or intensive care units at harborview medical center exclusion criteria: -

Keywords: education suicide prevention fidelity artificial intelligence
hypofractionated postoperative regional nodal irradiation for patients with intermediate-risk breast cancer

Conditions: Breast Carcinoma

Summary: the role of postoperative regional nodal irradiation (rni) for t1-2n1 intermediate-risk breast cancer is controversial, and there is a lack of class i evidence of a survival benefit from rni. a number of retrospective studies of breast cancer patient been undertaken to risk stratify, analyse site of recurrence and assess the role of radiotherapy. rni is currently recommended for patients at high risk of recurrence, but prospective studies in other patients are needed to assess the role of rni. two randomised phase iii trials have confirmed the safety and efficacy of 15-fraction hypofractionated radiotherapy, while 5-fraction super-hypofractionated radiotherapy to further shorten the course of radiotherapy is a hotspot of current research. the present study aimed to investigate whether rni improves the outcome of intermediate-risk breast cancer patients; and to assess the efficacy and toxicity of 15-fraction hypofractionated and 5-fraction super-hypofractionated radiotherapy.


Eligibility criteria:
inclusion criteria: 1. ≥45 years old 2. receiving breast-conserving surgery or total mastectomy and axillary lymph node dissection or sentinel lymph node biopsy 3. negative surgical margins 4. tumor staging： a. patients without neoadjuvant chemotherapy: pt1-2n1m0, axillary lymph node dissection with 1-3 metastatic lymph nodes, at least 1 lymph node with macroscopic metastasis, and a score of 0-2 according to the following risk factors: ≤40 years of age (1 point), tumour located in the inner quadrant (1 point), 2-3 lymph nodes positive in the axilla (1 point), presence of choroidal tumour thrombus (1 point), and restaging according to the 8th edition of the staging criteria (ib-iia 1 point, and iib-iiia 2 points) b. patients without neoadjuvant chemotherapy: pt1-2n1m0, sentinel lymph node biopsy with 1-2 metastatic lymph nodes, at least 1 lymph node with macroscopic metastasis, and a score of 0-2 according to the following risk factors: ≤40 years of age (1 point), tumour located in the inner quadrant (1 point), 2-3 lymph nodes positive in the axilla (1 point), presence of choroidal tumour thrombus (1 point), and restaging according to the 8th edition of the staging criteria (ib-iia 1 point, and iib-iiia 2 points) c. patients with neoadjuvant chemotherapy: ct1-2n1-2m0→ypt0-2n0m0, requiring positive clinical lymph nodes with pathological confirmation, receiving ≥6 cycles of neoadjuvant chemotherapy, and ≥3 sentinel lymph nodes detected for those with simple sentinel lymph node biopsy 5. signed informed consent exclusion criteria: 1. distant metastases 2. metastasis to ipsilateral internal breast, supraclavicular or subclavicular lymph nodes 3. previous radiotherapy to the chest 4. bilateral breast cancer 5. pregnancy, breastfeeding 6. previous or concurrent other malignancy with tumor-free survival \<5 years (but excluding skin cancer with non-malignant melanoma, papillary/follicular thyroid cancer, cervical carcinoma in situ)